-
11:12:00 PM

ANIP Stock News

11/28/22 6:50 AM
Nasdaq : ANIP
fda approvallow float
ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP
ANI Pharmaceuticals, Inc. today announced that the Company received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Fluoxetine Oral Solution, USP 20 mg/5 mL. The current annual U.S. market for Fluoxetine Oral Solution is approximately $14.6 million, according to IQVIA/IMS Health, a leading healthcare data and...
RHEA-AI
neutral
11/16/22 6:50 AM
Nasdaq : ANIP
fda approvallow float
ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP
ANI Pharmaceuticals, Inc. today announced that it received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Trimethoprim Tablets USP, 100 mg. The current annual U.S. market for Trimethoprim Tablets is approximately $16.8 million, according to IQVIA/IMS Health, a leading healthcare data and analytics provider.
RHEA-AI
very positive
11/09/22 6:50 AM
Nasdaq : ANIP
earningslow float
ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues
ANI Pharmaceuticals, Inc. today announced business highlights and financial results for the three and nine months ended September 30, 2022. We are pleased to share that ANI delivered record net revenues of $83.8 million and significant sequential gains of non-GAAP EBITDA, which at $19.6 million is nearly double that of the second quarter of 2022.
RHEA-AI
neutral
10/24/22 6:50 AM
Nasdaq : ANIP
earningslow float
ANI Pharmaceuticals to Discuss Third Quarter 2022 Financial Results on November 9, 2022, at 8:00 a.m. ET
ANI Pharmaceuticals, Inc. today announced that the Company will release its third quarter 2022 financial results on Wednesday, November 9, 2022, prior to market open. ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription...
RHEA-AI
neutral
08/30/22 4:05 PM
Nasdaq : ANIP
conferenceslow float
ANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
ANI Pharmaceuticals, Inc. today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the H.C. ANI Pharmaceuticals, Inc. is a diversified biopharmaceutical company serving patients in need by developing, manufacturing, and marketing high quality branded and generic prescription...
RHEA-AI
neutral
08/16/22 6:50 AM
Nasdaq : ANIP
fda approvallow float
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP
ANI Pharmaceuticals, Inc. today announced that the Company received U.S. Food and Drug Administration approval for the Abbreviated New Drug Application for Dexamethasone Tablets USP 1.5 mg, 4 mg and 6 mg. The current annual U.S. market for Dexamethasone Tablets USP 1.5 mg, 4 mg and 6 mg is approximately $59.8 million, according to IQVIA/IMS Health, a leading...
RHEA-AI
very positive
08/08/22 6:50 AM
Nasdaq : ANIP
earningslow float
ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin® Gel
ANI Pharmaceuticals, Inc. today announced business highlights and financial results for the three and six months ended June 30, 2022. “Second quarter net revenues of $73.9 million represent a new quarterly record for the Company, driven by the first full quarter of Purified Cortrophin Gel sales and growth in generic pharmaceuticals revenues.
RHEA-AI
neutral